Minghui Qiu

Keyan Zhou, Zecheng Tang, Lingfeng Ming et al.

The rapid advancement of large vision language models (LVLMs) has led to a significant expansion of their context windows. However, an extended context window does not guarantee the effective utilization of the context, posing a critical challenge for real-world applications. Current evaluations of such long-context faithfulness are predominantly focused on the text-only domain, while multimodal assessments remain limited to short contexts. To bridge this gap, we introduce MMLongCite, a comprehensive benchmark designed to evaluate the fidelity of LVLMs in long-context scenarios. MMLongCite comprises 8 distinct tasks spanning 6 context length intervals and incorporates diverse modalities, including text, images, and videos. Our evaluation of state-of-the-art LVLMs reveals their limited faithfulness in handling long multimodal contexts. Furthermore, we provide an in-depth analysis of how context length and the position of crucial content affect the faithfulness of these models.

Meng Wang, Tian Lin, Aidi Lin et al.

Previous foundation models for fundus images were pre-trained with limited disease categories and knowledge base. Here we introduce a knowledge-rich vision-language model (RetiZero) that leverages knowledge from more than 400 fundus diseases. For RetiZero's pretraining, we compiled 341,896 fundus images paired with texts, sourced from public datasets, ophthalmic literature, and online resources, encompassing a diverse range of diseases across multiple ethnicities and countries. RetiZero exhibits remarkable performance in several downstream tasks, including zero-shot disease recognition, image-to-image retrieval, AI-assisted clinical diagnosis,few-shot fine-tuning, and internal- and cross-domain disease identification. In zero-shot scenarios, RetiZero achieves Top-5 accuracies of 0.843 for 15 diseases and 0.756 for 52 diseases. For image retrieval, it achieves Top-5 scores of 0.950 and 0.886 for the same sets, respectively. AI-assisted clinical diagnosis results show that RetiZero's Top-3 zero-shot performance surpasses the average of 19 ophthalmologists from Singapore, China, and the United States. RetiZero substantially enhances clinicians' accuracy in diagnosing fundus diseases, in particularly rare ones. These findings underscore the value of integrating the RetiZero into clinical settings, where various fundus diseases are encountered.